---
layout: minimal-medicine
title: Nifurtimox
---

# Nifurtimox
### Generic Name
Nifurtimox

### Usage
Nifurtimox is primarily used to treat Chagas disease (American trypanosomiasis), a parasitic infection caused by the *Trypanosoma cruzi* parasite.  It's currently approved for use in pediatric patients (less than 18 years of age and weighing at least 2.5 kg).  While research continues, its effectiveness in adults is less established and often requires careful consideration due to potential side effects.  Nifurtimox is not a first-line treatment for Chagas disease in all regions and its use should be guided by a healthcare professional experienced in managing this infection.

### Dosage
Nifurtimox dosage is determined by the patient's weight and is typically administered three times a day (TID). The recommended dosage for pediatric patients is as follows:

* **Children 2.5 to < 40 kg:** 10-20 mg/kg/day in 3 divided doses for 60 days
* **Children â‰¥ 40 kg:** 8-10 mg/kg/day in 3 divided doses for 60 days

More specific weight-based recommendations (found in the provided data) should be followed.  The medication is administered orally; tablets can be crushed and mixed with food if needed.  Dosage adjustments for hepatic or renal impairment are not explicitly provided in current guidelines but caution is advised in patients with severe dysfunction in either organ system.

### Side Effects
Nifurtimox can cause several side effects, varying in frequency:


**Common (occurring in >10% of patients):**

* Headache
* Abdominal pain
* Decreased appetite
* Vomiting


**Less Common (occurring in 1-10% of patients):**

* Dizziness
* Diarrhea
* Nausea
* Skin rash (urticaria)
* Weight loss
* Anemia
* Eosinophilia (increased eosinophils in the blood)
* Fever


**Rare (occurring in <1% of patients):**

* Anxiety
* Drowsiness
* Fatigue
* Irritability
* Paresthesia (numbness or tingling)
* Seizures
* Vertigo
* Pruritus (itching)
* Syncope (fainting)
* Leukopenia (low white blood cell count)
* Neutropenia (low neutrophil count)
* Arthralgia (joint pain)
* Asthenia (weakness)
* Myalgia (muscle pain)
* Tremor


**Post-marketing reports:** Thrombocytopenia (low platelet count), anaphylaxis, angioedema, hypersensitivity reactions, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), agitation, amnesia, apathy, myasthenia, polyneuropathy, psychotic symptoms, and sleep disorders have been reported.

**Important Note:**  Any new or worsening symptoms should be reported to a healthcare provider immediately.


### How it Works
The precise mechanism of Nifurtimox is not fully understood. However, it is believed that the drug is metabolized by enzymes within the parasite (*Trypanosoma cruzi*) into toxic compounds.  These toxic metabolites damage the parasite's DNA and ultimately lead to its death.  The process involves reactive oxygen species that cause oxidative stress within the parasite.

### Precautions
* **Contraindications:** Nifurtimox is contraindicated in individuals with hypersensitivity to the drug or its components, and those consuming alcohol during treatment.
* **Pregnancy and Breastfeeding:** Nifurtimox can harm a developing fetus and is excreted in breast milk; therefore, it should be avoided during pregnancy and breastfeeding unless the potential benefits outweigh the risks.  Close monitoring of breastfed infants is necessary.
* **Renal and Hepatic Impairment:** Caution is advised in patients with impaired liver or kidney function.  Close monitoring is particularly crucial for those with severe renal impairment or end-stage renal disease on hemodialysis.
* **Neurological and Psychiatric Conditions:**  Nifurtimox may exacerbate pre-existing neurological or psychiatric conditions. It should be used cautiously in patients with a history of brain injury, seizures, psychiatric disorders, or serious behavioral problems.
* **Porphyria:** Nifurtimox can precipitate acute attacks in individuals with porphyria.
* **Drug Interactions:** Concurrent alcohol use may increase the risk and severity of adverse effects.
* **Other Precautions:** Patients should be monitored regularly for side effects, including complete blood counts (CBCs), liver function tests, and kidney function tests.  Body weight monitoring is also essential during extended treatment courses.


### FAQs

* **Q: Can I drink alcohol while taking Nifurtimox?**  A: No, alcohol consumption should be strictly avoided during treatment.
* **Q: What should I do if I miss a dose?** A: Take the missed dose as soon as possible with food. If it's close to the next dose (within 3 hours), skip the missed dose and continue with the regular schedule. Do not double the dose.
* **Q: How long does treatment usually last?** A: The typical treatment duration is 60 days, but this can vary depending on individual circumstances and the healthcare provider's recommendations. Completing the full course is crucial to prevent infection recurrence.
* **Q: What are the long-term effects of Nifurtimox?** A: Long-term effects are not fully established, but studies are ongoing.  Regular monitoring is important to detect and manage potential side effects.
* **Q:  Is Nifurtimox suitable for adults?** A: While it is used off-label in adults in some circumstances, its efficacy is less established than in children, and the risk-benefit ratio needs careful evaluation on a case-by-case basis.  It should only be used under the strict guidance of a physician experienced in treating Chagas disease.
* **Q: How should I store Nifurtimox?** A: Store as directed on the product label, typically in a cool, dry place away from direct sunlight and moisture.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Always consult with a healthcare professional before starting or changing any medication, especially if you are pregnant, breastfeeding, or have pre-existing health conditions.  The provided dosage information is for general guidance only and may not be suitable for all individuals.  Always follow your doctor's specific instructions.
